From: John McKenney [jmckenney@secassociates.com]
Sent: Friday, July 09, 2004 3:37 PM
To: fdadockets@oc.fda.gov
Cc: John McKenney; Diana Elvington
Subject: Comments to Docket No. 2004N-0133

Dear Sir or Madam:

The attached comments are submitted for FDA Docket No. 2004N-0133 regarding 21 CFR Part 11.  Please contact me if there are any questions or problems with this submission.

Thank you,


=================================
John McKenney
President & CEO
SEC Associates, Inc.
Email:  jmckenney@secassociates.com
Web:  www.secassociates.com
Ph:  919-467-1997


Confidentiality Notice: This e-mail transmission and any attachments may contain confidential or legally privileged information that is intended only for the person to whom it was addressed. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail is strictly prohibited. If you have received this e-mail transmission in error, please reply to the sender, so that SEC Associates can arrange for proper delivery, and then please delete the message from your Inbox. Thank you.